Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation

ResearchMoz added Latest Research Report titled " Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation " to it's Large Report database.

Pancreatic cancer is the 12th most common cancer globally, and the fourth most fatal, with a mortality rate of 10.9 deaths per 100,000 people per year. The poor prognosis of pancreatic cancer patients has highlighted a significant need for new and improved approaches to treatment, which is not being met by the current market.

A highly active pancreatic cancer pipeline contains an array of products with varying molecule types and mechanisms of action, which provides a striking contrast to the current, chemotherapy dominated, market. Within the pipeline, there are 185 products that act on a first-in-class molecular target, representing 52% of the total pancreatic cancer pipeline products that have a disclosed molecular target. A drastically different pipeline and market composition implies that the approach to pancreatic cancer treatment is changing and first-in-class innovation is playing a significant role in this.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=294920

Scope
  • Gemcitabine based regimens continue to dominate the market, which has seen few new entrants over the past decade. The continued reliance on generic chemotherapies is one reason why the prognosis has shown little improvement.
  • What survival benefits do current therapies provide?
  • What are the current unmet needs that the pipeline needs to address?
  • The pipeline contains a plethora of molecule types and molecular targets not present on the market, including a large focus on therapies targeting common oncogenic pathways and signaling intermediates such as PI3K/Akt.
  • What impact will the emergence of biologics have on the pancreatic cancer landscape?
  • Will pipeline diversity translate to clinically and commercially successful therapies?
  • How will the rise of novel molecular target categories, such as signal transduction, impact future treatment options?
  • 52% of pipeline products act on a first-in-class target, which is higher than the oncology and industry averages.
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 4
2.1 Large and Diverse Pipeline Contrasts the Limited Market 4
2.2 Pancreatic Cancer Shows High Levels of First-in-Class Innovation 4
2.3 High Deal Activity Reflects Dynamic Pipeline 4

3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Developments Remain Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report Guidance 8

4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.2 Disease Symptoms 9
4.3 Epidemiology 9
4.4 Etiology 10
4.4.1 Risk Factors 10
4.4.2 Medical Conditions Leading to Pancreatic Cancer 10
4.4.3 Genetic Conditions Leading to Pancreatic Cancer 10
4.4.4 Conclusion 11

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation Reviewed by Sagar Jagtap on 03:38 Rating: 5

No comments:

Powered by Blogger.